Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials

BackgroundAnti-PD-1 monotherapy is the standard therapy for advanced melanoma patients, including those with NRAS mutations. The influence of NRAS mutation on immunotherapy, especially in noncutaneous melanoma, is largely uncharacterized.Materials and MethodsWe analyzed clinical data of four clinica...

Full description

Bibliographic Details
Main Authors: Li Zhou, Xuan Wang, Zhihong Chi, Xinan Sheng, Yan Kong, Lili Mao, Bin Lian, Bixia Tang, Xieqiao Yan, Xue Bai, Siming Li, Jun Guo, Chuanliang Cui, Lu Si
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
NRAS
noncutaneous melanoma
cutaneous melanoma
immunotherapy
anti-PD-1 monotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.691032/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.691032/full

Similar Items